ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA(R) is listed in the "Lauer-Taxe" (Grosse Deutsche Spezialitatentaxe) with an ex-factory price of EUR3,078... via Health News from Medical News Today Read More Here..
No comments:
Post a Comment